ARTL

Artelo BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

15%

Probability

Target price

$3.00

+106.9% vs current

Most likely

Base case

70%

Probability

Target price

$1.42

-2.1% vs current

B-

Bear case

15%

Probability

Target price

$0.80

-44.8% vs current

AI sentiment snapshot

Latest data as of 2026-03-03

AI commentary

Coverage is thin with wide target dispersion: median near $1.42 but notable outliers. Market attention is split between binary upside from positive readouts/partnerships and downside from dilution/runway risk, producing headline-driven volatility and moderate conviction [#SERP-2][#SERP-7].

RankAlpha Sentiment AI - 2026-03-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-01catalystPotential near-term financing or partnershipHigh impact

Company is likely to pursue financing or a partnership to fund clinical programs; conservative 90-day estimate used for timing. Near-term financing would dilute equity but could also catalyze a re-rating if structured as a strategic partner deal [#SERP-2].

2026-09-30eventClinical readout or trial update (assumed window end)High impact

Estimated trial update or data communication by the conservative window end date; binary readouts can move the stock materially in either direction [#SERP-1].

2027-03-03catalystCommercialization/strategic milestoneHigh impact

Successful partnering, licensing, or early commercialization pathway materializing over a 12-month horizon; >100% expected_move is driven by a binary outcome (positive readout + partnership or acquisition) that meaningfully de-risks the pipeline and expands valuation multiples [#SERP-9].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-03-03 • Updated nightlySource: Internal modelMethodology